AXA China Region Insurance Company (Bermuda) Limited has entered into a formal partnership with the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration.
The agreement focuses on jointly developing innovative medical insurance models by utilising the advanced healthcare facilities and resources available in the Boao Lecheng Pilot Zone, enhancing cross-border medical options for customers.
Established in 2013 with approval from China’s State Council, the Hainan Boao Lecheng International Medical Tourism Pilot Zone operates as a unique medical special zone in China.
The zone benefits from preferential policies that facilitate licensed medical services, research initiatives, and international healthcare exchanges.
Since its inception, it has attracted leading medical institutions and expert teams to introduce international treatment protocols, pioneering pharmaceuticals, and medical devices for trial within China, including cutting-edge therapies for rare diseases and certain cancers.
Additionally, AXA is collaborating with China Biotech Services Holdings Limited to advance Boron Neutron Capture Therapy (BNCT), an innovative cancer treatment being developed within the zone.
A senior executive from AXA highlighted the strategic value of this partnership.
“This collaboration will enable AXA to explore innovative healthcare solutions and integrate them into our insurance offerings, providing customers with broader access to advanced treatment options. We look forward to deepening our partnership with Lecheng and other stakeholders to develop innovative medical models, enabling more customers to benefit from Lecheng’s licensed medicines, medical devices, and cutting-edge technologies,” said Janet Lee, chief life and health insurance officer, AXA Hong Kong and Macau.
Following the partnership, AXA Hong Kong and Macau rolled out “AXA Health Concierge,” a health management platform designed to facilitate smoother access to medical care across Hong Kong and Mainland China.
The platform features the “Green Medical Pass,” which grants priority appointment scheduling with a network of over 2,000 healthcare providers, including more than 500 doctors spanning 30 specialties across both regions.
This initiative addresses ongoing challenges within Hong Kong’s healthcare system, where outpatient specialist waiting times have reached extended durations, in some cases exceeding two years.
Meanwhile, as Mainland China continues to expand its medical infrastructure, cross-border healthcare access has become increasingly relevant.
For instance, the Shenzhen Health Commission reported more than 700,000 consultations provided to Hong Kong residents in 2023 alone.
AXA’s life and health insurance leadership noted that cross-border medical interactions have grown following the pandemic, with more Hong Kong residents seeking treatment in Mainland China.
The new service is designed to connect policyholders with a wider spectrum of healthcare options, supporting timely treatment and ongoing care.
